Pacific Bio (NASDAQ: PACB) reported Q3 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $55.69 million versus the consensus estimate of $48.72 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.